Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.

Completed

Brief Summary: The purpose of this study is to collect safety information on the use of Fluarix Tetra according to the approved PI, in Korea, over a period of 6 years from children greater than or equal to (≥)3 years of age and adults, and over a period of 4 years from children between 6 months and 35 months of age.

Detailed Description: Adults and previously vaccinated children aged ≥6 months, a single dose of Fluarix Tetra will be administered. To previously unvaccinated children aged 6 months to less than (\<) 9 years, two doses will be administered with a second dose at least 4 weeks apart from the first one as per the local PI in Korea.

Fluarix Tetra may be administered to pregnant women/lactating women as per PI, if there is a clear need. Pregnancy outcome (whether full-term or premature, information on the status of the mother and child) in vaccinated pregnant subjects will be followed-up at 6-8 weeks after delivery, if possible.

Recruitment & Eligibility

Inclusion Criteria

Male or female subjects who were vaccinated with Fluarix Tetra or eligible to receive Fluarix Tetra according to the locally approved PI.
Signed informed consent as Informed Consent Form (ICF)/Informed Assent Form (IAF) obtained from the subject/subject's parent(s)/Legally acceptable Representative(s) [LAR(s)].

Exclusion Criteria

Those who are not eligible for vaccination with Fluarix Tetra according to the local PI.
- Hypersensitivity reaction to Fluarix Tetra.
- History of hypersensitivity reaction to Influenza vaccine.
- History of Guillain-Barre syndrome or other nervous system abnormalities to Influenza vaccine within 6 weeks post-vaccination.
Those who are not eligible for vaccination with Fluarix Tetra according to the medical judgement of physician.

Arm && Interventions

Group	Intervention	Description
Fluarix Tetra Group 2	Data collection	Subjects aged 3 years and above who received Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
Fluarix Tetra Group 1	Data collection	Subjects aged between 6-35 months old who received Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).

Primary Outcome Measures

Name	Time	Method
Number of Participants With Serious Adverse Events (SAEs)	During the 21 days follow-up period after vaccination (i.e. day of vaccination and 20 subsequent days)	SAEs assessed included any adverse event that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study subject.
Number of Participants With Unexpected Adverse Events (AEs)	During the 21 days follow-up period after vaccination (i.e. day of vaccination and 20 subsequent days)	Any adverse event reported in addition to those expected during the drug use investigation. Adverse events that are not reflected in the approved Prescribing Information.
Number of Participants With Expected Adverse Events (AEs)	During the 21 days follow-up period after vaccination (i.e. day of vaccination and 20 subsequent days)	An adverse event that is expected from the subject during the post-vaccination follow-up period as described in the locally approved Prescribing Information.

Secondary Outcome Measures

Name	Time	Method

Locations (1): GSK Investigational Site
🇰🇷
Yangju-si, Gyeonggi-do, Korea, Republic of

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial